- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05834062
Phentermine/Topiramate as Preventive Pharmacotherapy for Obesity
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will evaluate the effects of preventative pharmacotherapy on body mass index (BMI), as well as incidence of obesity and normal weight, in adolescents at high risk of developing obesity. We hypothesize that 24 months of Qsymia vs. placebo, in combination with lifestyle-based weight gain prevention coaching, will prevent increases in BMI (primary endpoint). More participants in the placebo group will develop obesity (cross the BMI 30 kg/m2 threshold) and more in the Qsymia group will transition to normal weight (drop below a BMI of 25 kg/m2).
All participants, regardless of medication/placebo assignment, will receive the same foundational weight gain prevention coaching throughout the entire study. The weight gain prevention coaching will be delivered individually by master's level behavioral intervention specialists with expertise in nutrition, physical activity, and weight-related behavior change. The multi-phase prevention intervention will start with 6 weekly 30-minute coaching calls followed by monthly 15-minute check-in calls for the remainder of the first year. At the beginning of the second year, a series of 3, 30-minute coaching calls will be held to revisit the information covered in the initial coaching calls, followed by bi-monthly 15-minute check-in calls for the remainder of the second year. The calls will be conducted via videoconference substituted with phone calls if needed.
The weight gain prevention intervention will utilize empirically supported behavior change strategies to help promote healthy dietary intake, physical activity patterns, and modest weight loss and/or prevent weight gain among participants. The intervention is informed by several of our previous weight loss and maintenance trials and the work of others, including weight gain prevention trials in young adult populations. The core prevention intervention is based on a behavioral conceptualization of effective weight management that emphasizes: 1) identifying behaviors in need of change; 2) setting goals for change; 3) monitoring progress; 4) modifying environmental cues to facilitate change; and 5) modifying consequences to motivate change. The intervention will incorporate core behavior change strategies including self-monitoring, stimulus control, modeling, goal setting, and positive reinforcement, which were among the common behavior change elements identified across the 17 treatment arms used in the Early Adult Reduction of weight through LifestYle (EARLY) weight management trials that included the young adult weight gain prevention trials previously referenced.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55414
- University of Minnesota
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 16 to less than 22 years at screening
- BMI >/= 25 to < 30 kg/m^2
- Family history of obesity defined as one biological parent with severe obesity (BMI >/= 35) and/or two biological parents with obesity (BMI >/= 30)
- Age 16 or 17 years old must also have an obesity-related complication/co-morbidity defined as elevated blood pressure (>/= 130 and/or >/= 80 milligrams of mercury [mmHg]) or current use of anti-hypertensive medication, dyslipidemia (triglycerides >/= 150 milligrams/deciliter (mg/dL) and/or HDL cholesterol < 40 mg/dL or current use of cholesterol-lowering medication, diagnosis of obstructive sleep apnea
Exclusion Criteria:
- Tanner stage 1-4
- Diabetes (1 or 2)
- Current or recent (< 6 months prior to enrollment) use of anti-obesity medication(s) and other weight-altering medication(s) (e.g.,, atypical antipsychotics, attention-deficit hyperactivity disorder [ADHD] stimulant)
- Previous bariatric surgery
- Current or recent (< 6 months prior to enrollment) use of medication(s) to treat insulin resistance
- Recent initiation (< 3 months prior to enrollment) of anti-hypertensive or lipid medication(s)
- History of glaucoma
- Current or recent (< 14 days) use of monoamine oxidase inhibitor
- Known hypersensitivity to sympathomimetic amines
- History of treatment with growth hormone
- Patient Health Questionnaire (PHQ) score of >/= 15
- Eating disorder symptoms within 6 months and/r any past medical diagnosis of eating disorder
- Major psychiatric disorder
- Unstable clinically-diagnosed depression
- History of suicide attempt
- Suicidal ideation of type 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) in the last month
- Current pregnancy or breastfeeding
- Plans to become pregnant
- If sexually active, refusal to use 2 forms of birth control
- Tobacco use
- Alanine transaminase (ALT ) or Aspartate transaminase (AST) >/= 2.5 the upper limit of normal
- Bicarbonate < 18 micromoles per liter (mmol/L)
- Creatinine 1.2 mg/dL
- Creatinine clearance of < 50 microliters per minute [mL/min] (Schwartz formula)
- History of seizures
- Uncontrolled hypertension
- History of structural heart defect
- History of clinically significant arrhythmia
- Diagnosed monogenic obesity
- History of cholelithiasis
- History of nephrolithiasis
- Hyperthyroidism
- Untreated thyroid disorder
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Medication arm
Individuals randomized to this group will be offered lifestyle-based weight gain prevention counseling. Participants will initiate treatment at 3.75 mg/23 mg orally once in the morning for 14 days, which will then be increased to 7.5 mg/46 mg orally once daily in the morning for the remainder of the trial. Participants who are unable to tolerate the dosing regimen will be maintained at the maximally tolerated dose. To further safeguard the risk/benefit balance we will utilize a down-titration protocol for participants who experience a reduction in BMI below a threshold of 20 kg/m2. In this case, participants will be reduced to the lowest-dose level (3.75 mg/23 mg) for 12 weeks. If the BMI remains below 20 kg/m2 at the lowest dose after 12 weeks, active treatment will be fully withdrawn. Participants at the end of the study will be down-titrated gradually with instructions to take the medication every other day for 7 days before stopping treatment altogether. |
Qsymia will be used at 3.7g mg/23 mg for 12 weeks and then increased to 7.5 mg/46 mg for the remainder of the study.
Participants will be offered lifestyle management therapy.
|
Placebo Comparator: Placebo arm
Individuals randomized to this group will be offered lifestyle-based weight gain prevention counseling. Participants will initiate treatment with a placebo (to keep the blind) and be asked to up-titrate the placebo dose after the first 14 days and then maintain the placebo dose for the remainder of the study. Individuals who are unable to tolerate the dosing regimen will have a down-titration protocol (to maintain the blind) as described in the medication arm. Likewise, we will employ a down-titration protocol for participants who experience a reduction in BMI below a threshold of 20 kg/m2. In this case, participants would be reduced to the lowest dose level of placebo for 12 weeks. If the BMI remains below 20 kg/m2 after 12 weeks, placebo treatment will be fully withdrawn. Individuals in the placebo arm will also have a placebo-based down-titration with instructions to take the placebo every other day for 7 days before stopping treatment altogether, to maintain the blind. |
Placebo will be used in lieu of Qsymia to maintain the blind.
Participants will be offered lifestyle management therapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate effects of preventive pharmacotherapy and lifestyle-based weight gain prevention on body mass index between the medication arm and the placebo arm
Time Frame: 24 months
|
Change in BMI
|
24 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PEDS-2022-31025
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity, Adolescent
-
National University of MalaysiaUniversiti Putra Malaysia; University of RoehamptonCompletedAdolescent Obesity | Adolescent Behavior | Adolescent OverweightMalaysia
-
University of OxfordOxford Brookes UniversityRecruitingOverweight/Obesity, AdolescentUnited Kingdom
-
VIVUS LLCCompletedAdolescent Obesity | Obesity in Adolescence | Adolescent OverweightUnited States
-
Delta University for Science and TechnologyCompletedObesity, Adolescent | Adolescent DevelopmentEgypt
-
State University of New York at BuffaloNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedObesity, Adolescent | Adolescent Behavior
-
Children's Hospital of PhiladelphiaUniversity of Pennsylvania; National Institutes of Health (NIH); National Center...Not yet recruitingAdolescent Obesity | Diet, Healthy | Adolescent OverweightUnited States
-
University of BedfordshireCompletedInsulin Resistance | Adolescent Obesity | Adolescent BehaviorUnited Kingdom
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
-
Guangzhou Sport UniversityUnknownChildhood Obesity | Adolescent ObesityChina
Clinical Trials on Qsymia and lifestyle management therapy
-
UConn HealthNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Penn... and other collaboratorsCompletedDepression | DiabetesUnited States
-
Seoul National University HospitalRecruitingWeight Change, BodyKorea, Republic of
-
Tampere UniversityTampere University Hospital; Sitra, the Finnish Innovation FundCompletedHypertension | Diabetes | Dyslipidemias | Overweight and ObesityFinland
-
Northwestern UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Osteoarthritis, KneeUnited States
-
University of PittsburghU.S. Air Force Office of the Surgeon GeneralCompleted
-
The University of Texas Health Science Center,...Active, not recruitingCoronary Artery Disease | Cardiovascular Disease | Atherosclerosis | Coronary StenosisUnited States
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH); Mount Zion...Completed
-
The Hong Kong Polytechnic UniversityNot yet recruiting
-
NYU Langone HealthCompletedCardiovascular DiseaseUnited States
-
Duke UniversityAmerican College of RheumatologyCompletedPain | Obesity | Rheumatoid ArthritisUnited States